Zydus receives EIR with Voluntary Action Indicated (VAI) from USFDA for its Moraiya formulations manufacturing facility

Ahmedabad, India, November 07, 2022

Zydus Lifesciences Ltd. (including its subsidiaries, together referred to as "Zydus"), an innovation driven global lifesciences company announced the receipt of an Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its formulations manufacturing facility in Moraiya, near Ahmedabad, India. The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI). The USFDA had inspected the facility from 26th July to 5th August, 2022 which concluded with four observations. The USFDA has indicated that the inspection is closed.

About Zydus

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 23000 people worldwide and is driven by its mission to unlock new possibilities in life-sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through path-breaking discoveries. For more details visit www.zyduslife.com.

***

PRESS RELEASE

For further information please contact :
The Corporate Communications Department

Zydus Lifesciences Limited
(formerly known as Cadila Healthcare Limited)
Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000 | website : www.zyduslife.com
CIN : L24230GJ1995PLC025878